Cargando…

A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study

BACKGROUND: Direct stimulation of the afferent nerve endings in the venous endothelium is one explanation of propofol injection pain. Previous studies found that ondansetron can also block sodium channels. This effect is similar to that of lidocaine. OBJECTIVE: The primary outcome was the efficacy o...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasinwong, Wirat, Termthong, Sarocha, Plansangkate, Prae, Tanasansuttiporn, Jutarat, Kosem, Riam, Chaofan, Surewan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014613/
https://www.ncbi.nlm.nih.gov/pubmed/35436859
http://dx.doi.org/10.1186/s12871-022-01650-4
_version_ 1784688220881027072
author Wasinwong, Wirat
Termthong, Sarocha
Plansangkate, Prae
Tanasansuttiporn, Jutarat
Kosem, Riam
Chaofan, Surewan
author_facet Wasinwong, Wirat
Termthong, Sarocha
Plansangkate, Prae
Tanasansuttiporn, Jutarat
Kosem, Riam
Chaofan, Surewan
author_sort Wasinwong, Wirat
collection PubMed
description BACKGROUND: Direct stimulation of the afferent nerve endings in the venous endothelium is one explanation of propofol injection pain. Previous studies found that ondansetron can also block sodium channels. This effect is similar to that of lidocaine. OBJECTIVE: The primary outcome was the efficacy of ondansetron compared to lidocaine and placebo for the reduction of propofol injection pain. METHOD: This trial was conducted in 240 patients, American Society of Anesthesiologists classification I-III and aged between 18–65 years old, undergoing elective surgery, and having a 20-gauge intravenous catheter at the hand dorsum. Each group of 80 patients received 8 mg. of ondansetron in the O Group, 40 mg. of lidocaine in the L Group and normal saline in the C Group. The study medications were blindly administered to the patients through a 20-gauge intravenous catheter placed on the hand dorsum, and then 1 min later, the small dose of propofol (50 mg.) was infused via the syringe pump at a rate of 600 ml/hr. for 30 s. Following that, the syringe pump of propofol was temporarily stopped, and the patients were asked to rate their pain at the injection site. RESULT: The incidence of pain was lowest in the L group (66.2%) compared with the O (82.5%) and the C groups (85.0%) (P < 0.01). The median pain score in the L, O, and C groups were 2 (0–4), 4 (2–5), and 4.5 (2–6), respectively (P < 0.01). The incidences of no pain, mild, moderate, and severe pain were also significantly different in the L group (33.8%, 37.5%, 21.2%, and 7.5%, respectively) compared with those in the O group (17.5%, 31.2%, 31.2%, and 20.0%, respectively) and the C groups (15.0%, 22.5%, 40.0%, and 22.5%, respectively) (P < 0.01). CONCLUSION: Pretreatment with intravenous lidocaine, rather than ondansetron, can reduce the incidence and intensity of propofol-induced pain.
format Online
Article
Text
id pubmed-9014613
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90146132022-04-19 A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study Wasinwong, Wirat Termthong, Sarocha Plansangkate, Prae Tanasansuttiporn, Jutarat Kosem, Riam Chaofan, Surewan BMC Anesthesiol Research BACKGROUND: Direct stimulation of the afferent nerve endings in the venous endothelium is one explanation of propofol injection pain. Previous studies found that ondansetron can also block sodium channels. This effect is similar to that of lidocaine. OBJECTIVE: The primary outcome was the efficacy of ondansetron compared to lidocaine and placebo for the reduction of propofol injection pain. METHOD: This trial was conducted in 240 patients, American Society of Anesthesiologists classification I-III and aged between 18–65 years old, undergoing elective surgery, and having a 20-gauge intravenous catheter at the hand dorsum. Each group of 80 patients received 8 mg. of ondansetron in the O Group, 40 mg. of lidocaine in the L Group and normal saline in the C Group. The study medications were blindly administered to the patients through a 20-gauge intravenous catheter placed on the hand dorsum, and then 1 min later, the small dose of propofol (50 mg.) was infused via the syringe pump at a rate of 600 ml/hr. for 30 s. Following that, the syringe pump of propofol was temporarily stopped, and the patients were asked to rate their pain at the injection site. RESULT: The incidence of pain was lowest in the L group (66.2%) compared with the O (82.5%) and the C groups (85.0%) (P < 0.01). The median pain score in the L, O, and C groups were 2 (0–4), 4 (2–5), and 4.5 (2–6), respectively (P < 0.01). The incidences of no pain, mild, moderate, and severe pain were also significantly different in the L group (33.8%, 37.5%, 21.2%, and 7.5%, respectively) compared with those in the O group (17.5%, 31.2%, 31.2%, and 20.0%, respectively) and the C groups (15.0%, 22.5%, 40.0%, and 22.5%, respectively) (P < 0.01). CONCLUSION: Pretreatment with intravenous lidocaine, rather than ondansetron, can reduce the incidence and intensity of propofol-induced pain. BioMed Central 2022-04-18 /pmc/articles/PMC9014613/ /pubmed/35436859 http://dx.doi.org/10.1186/s12871-022-01650-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Wasinwong, Wirat
Termthong, Sarocha
Plansangkate, Prae
Tanasansuttiporn, Jutarat
Kosem, Riam
Chaofan, Surewan
A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study
title A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study
title_full A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study
title_fullStr A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study
title_full_unstemmed A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study
title_short A comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study
title_sort comparison of ondansetron and lidocaine in reducing injection pain of propofol: a randomized controlled study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9014613/
https://www.ncbi.nlm.nih.gov/pubmed/35436859
http://dx.doi.org/10.1186/s12871-022-01650-4
work_keys_str_mv AT wasinwongwirat acomparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT termthongsarocha acomparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT plansangkateprae acomparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT tanasansuttipornjutarat acomparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT kosemriam acomparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT chaofansurewan acomparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT wasinwongwirat comparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT termthongsarocha comparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT plansangkateprae comparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT tanasansuttipornjutarat comparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT kosemriam comparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy
AT chaofansurewan comparisonofondansetronandlidocaineinreducinginjectionpainofpropofolarandomizedcontrolledstudy